Skyrizi Alternatives Compared
| Skyrizi (risankizumab) | Otezla (apremilast) | Cosentyx (secukinumab) |
|
|---|
| Skyrizi (risankizumab) | Otezla (apremilast) | Cosentyx (secukinumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Skyrizi is an interleukin inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis (UC). The usual dosage is 150mg every 12 weeks... View more |
Prescription only
Otezla is a PDE4 inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease. It may also be used to treat plaque psoriasis... View more |
Prescription only
Cosentyx may be used to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa (HS), and some other conditions. After an initial loading dose, Cosentyx can be... View more |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
| More about Skyrizi (risankizumab) | More about Otezla (apremilast) | More about Cosentyx (secukinumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Skyrizi has an average rating of 8.0 out of 10 from a total of 60 ratings on Drugs.com. 73% of reviewers reported a positive effect, while 13% reported a negative effect. |
Otezla has an average rating of 5.2 out of 10 from a total of 443 ratings on Drugs.com. 35% of reviewers reported a positive effect, while 40% reported a negative effect. |
Cosentyx has an average rating of 6.3 out of 10 from a total of 253 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 30% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Skyrizi side effects |
View all Otezla side effects |
View all Cosentyx side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Skyrizi prices |
View all Otezla prices |
View all Cosentyx prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
672 hours |
9 hours |
744 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 191 drugs are known to interact with Skyrizi:
|
A total of 112 drugs are known to interact with Otezla:
|
A total of 252 drugs are known to interact with Cosentyx:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
April 23, 2019 |
March 21, 2014 |
January 21, 2015 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Otezla
Otezla (apremilast) is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers ...
Omvoh
Omvoh is used to treat moderate to severe ulcerative colitis or Crohn's disease in adults. This ...
Entyvio
Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn's disease, reducing ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Humira
Humira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...
Ilumya
Ilumya (tildrakizumab) is used to treat moderate-to-severe plaque psoriasis to reduce plaques ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Rinvoq
Rinvoq (upadacitinib) is used to treat rheumatoid arthritis, psoriatic arthritis, atopic ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.